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Abstract: Exosomes are one of the most important mediators of the cross talk occurring between
glioma stem cells (GSCs) and the surrounding microenvironment. We have previously shown that
exosomes released by patient-derived glioma-associated stem cells (GASC) are able to increase,
in vitro, the aggressiveness of both GSC and glioblastoma cell lines. To understand which molecules
are responsible for this tumour-supporting function, we performed a descriptive proteomic analysis
of GASC-exosomes and identified, among the others, Semaphorin7A (SEMA7A). SEMA7A was
described as a promigratory cue in physiological and pathological conditions, and we hypothesised
that it could modulate GSC migratory properties. Here, we described that SEMA7A is exposed on
GASC-exosomes’ surface and signals to GSC through Integrin β1. This interaction activates focal
adhesion kinase into GSC and increases their motility, in our patient-based in vitro model. Our
findings suggest SEMA7A-β1-integrin as a new target to disrupt the communication between GSCs
and the supporting microenvironment.
Keywords: glioblastoma microenvironment; exosomes; Semaphorin 7A; integrin β1/FAK signalling;
motility
1. Introduction
Despite a state-of-the art treatment, the median overall survival of glioblastoma multiforme
(GBM)’s patients is 14 months [1]. The lack of therapeutic efficacy is due to the great intertumour and
intratumour cellular and molecular heterogeneity, biological aggressiveness, the ability to develop drug
resistance, as well as the infiltrative nature of tumour cells into the surrounding brain parenchyma [2].
Infiltration makes impossible a radical surgery thus favouring recurrences within 1 to 2 cm from
the original tumour mass, appearing few months after the first diagnosis and treatment or being
already present at the time of the initial presentation [3]. Moreover, single infiltrating cells are often
spread throughout the entire brain parenchyma, escaping from surgery and treatment [4].
Several studies suggest that GBM’s tumour bulk contains a subpopulation of self-renewing
and highly tumorigenic stem cells named glioma stem cells (GSCs) [5,6], with tumour-initiating
properties that contribute to tumour growth and malignancy [7] through their sustained proliferation,
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invasion, stimulation of angiogenesis, ability to suppress immune responses and to develop resistance
to therapy [8,9]. As normal neural stem cells, GSCs reside in specialised niches, where they receive
maintenance stimuli and protection by interacting with the components of the surrounding milieu [5].
The tumour microenvironment contains various nontumoral cell types, such as endothelial cells,
tumour-associated macrophages (TAMs), pericytes, resident astrocytes, as well as extracellular matrix
components and secreted molecules such as growth and differentiation factors [5–7]. GSCs actively
remodel the microenvironment, establishing a continuous cross-talk, which maintains and contributes
to disease progression. Since the dialogue between GSCs and microenvironment gives a remarkable
support to GBM, identification of key actors playing in this scenario has become increasingly challenging.
Growing evidence highlight that extracellular vesicles (EV) are one of the most important
mediators of the cross-talk occurring in the tumour environment [10,11]. EV comprise a heterogeneous
group of vesicles with sizes ranging from 100 to 1000 nm that play an important role in intercellular
communication, by transporting complex cargoes [12,13]. Exosomes represent a subpopulation of EV
(50–150 nm) generated into multivesicular endosomes that direct bioactive molecules (RNA, microRNA,
proteins and lipids) to specific target cells, thereby altering their functions and/or reprogramming their
genomic landscape [14].
In glioma, communication mediated by exosomes has not been extensively studied. However,
some reports show the impact of tumour cell-derived exosomes on tumour biology [15,16].
Studies in breast and gastric cancer [17,18] have provided important information on the role of
stromal-derived exosomes in enhancing growth, invasion and motility of tumour cells, although the
molecular mechanisms by which exosomes exert their tumour-promoting role was not elucidated.
We have previously established a protocol to isolate a population of stem cells, named
glioma-associated stem cells (GASC) from human low- and high-grade gliomas. GASC are characterised
by an undifferentiated mesenchymal phenotype, clonogenicity and multipotency, in vitro [19,20].
This cell population is devoid of tumour-initiating property in vivo, and it do not show genetic
aberrations characterising the tumour of origin, nevertheless GASC show the ability to grow in an
anchorage-independent way. For these reasons, GASC represent bona fide glioma stromal cells,
residing in tumour microenvironment.
We have also demonstrated that GASC are characterised by the ability to support the biological
aggressiveness of tumour cells (both GSCs and immortalised tumour cell lines) in vitro, including their
motility, through the release of exosomes [19].
To understand which signals present in GASC exosomes are able to increase the aggressiveness of
GSCs, we analysed the protein content of exosomes isolated from GASC-conditioned medium and
found that, among other proteins, they transport Semaphorin 7A (SEMA7A).
Semaphorins are a family of secreted and membrane-bound glycoproteins, known as important
guidance signals in development of the central nervous system [21]. Semaphorins are expressed
also outside the Central Nervous System CNS and are involved in many other biological processes,
including regulation of cell survival, cell adhesion, motility, angiogenesis, immune response regulation
and tumour progression [22,23].
SEMA7A is traditionally described as a guidance cue for axon and neurite outgrowth [24,25]
and its biological effect could be mediated by interactions with two surface receptors: heterodimeric
integrinsα1β1 and Plexin C1 [26]. In human melanocytes, SEMA7A-integrinβ1 interaction is described
as a promoter of adhesion and dendricity [27], while the binding of SEMA7A to PlexinC1 inhibits
dendrites formation. SEMA7A is also responsible for monocytes migration, during inflammatory
processes [28] and is involved in the progression of ductal carcinoma, mediating growth, motility and
invasion [29].
Here we demonstrate that SEMA7A carried by GASC-derived exosomes enhances the motility of
GSCs, and suggest the mechanism of action via interaction with β1-integrin, expressed on GSCs surface.
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2. Results
2.1. Characterisation of GASC-Derived Exosomes
Four exosomes preparations obtained from GASC conditioned medium were first examined by
nanoparticle tracking analysis (NTA). Particle size ranged from 109.7 to 123.2 nm with an average
diameter of 115.5 ± 5.6 nm (Figure 1A). Vesicles were not detected in non-conditioned medium used as
a control.
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Figure 1. Characterisation of glioma associated stem cell (GASC)-derived exosomes. (A) 
Representative graphs of nanoparticle tracking analysis (NTA) on a preparation obtained from a 
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for 48 h by 4 GASC cell populations (Exo#1, Exo#2, Exo#3 and Exo#4). (B) Western Blotting for 
exosome-specific markers (tetraspanins CD63, CD9 and TSG-101) and for cell endoplasmic reticulum 
marker (calnexin) on 4 exosomes lysates (Exo#1–4) and on paired producing cells (GASC#1–4). 
As assessed by Western blot, exosome preparations were enriched in CD63 and CD9, two 
transmembrane tetraspanins used as exosomal markers, and in TSG101 (tumour susceptibility gene 
101)—a key component of the ESCRT-I complex (Endosomal Sorting Complex Required for 
Transport). Conversely, exosome preparations did not express Calnexin, an Endoplasmic Reticulum 
Protein, highly expressed in the cellular counterpart, thus excluding the presence of cellular 
contaminants (Figure 1B). 
Figure 1. Characterisation of glioma associated stem cell (GASC)-derived exosomes. (A) Representative
graphs of nanoparticle tracking analysis (NTA) on a preparation obtained from a nonconditioned
supernatant (Ctrl) and on exosomes (Exo) isolated from supernatants conditioned for 48 h by 4 GASC
cell populations (Exo#1, Exo#2, Exo#3 and Exo#4). (B) Western Blotting for exosome-specific markers
(tetraspanins CD63, CD9 and TSG-101) and for cell endoplasmic reticulum marker (calnexin) on 4
exosomes lysates (Exo#1–4) and on paired producing cells (GASC#1–4).
As assessed by Western blot, exosome preparations were enriched in CD63 and CD9, two
transmembrane tetraspanins used as exosomal markers, and in TSG101 (tumour susceptibility gene
101)—a key component of the ESCRT-I complex (Endosomal Sorting Complex Required for Transport).
Conversely, exosome preparations did not express Calnexin, an Endoplasmic Reticulum Protein, highly
expressed in the cellular counterpart, thus excluding the presence of cellular contaminants (Figure 1B).
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2.2. Proteomic Analysis
Protein content of exosomes from two different GASC cultures (S82 and S104) was analysed.
Protein lysates were separated on Sodyum Dodecyl-Sulphate PolyAcrylamide Gel Electrophoresis
SDS-PAGE and gel was cut to divide samples into six macrobands approximately corresponding to six
molecular weight fractions: >130 kDa; 97–130 kDa; 66–97 kDa; 47–66 kDa; 40–47 kDa; and 26–36 kDa.
Peptides obtained by in-gel trypsin digestion were analysed by liquid chromatography–tandem mass
spectroscopy (LC–MS/MS).
Sequence database searches were performed using the MASCOT software (Matrixscience.com)
giving a list of 316 elements (Tables S1 and S2). Four filtering steps have been applied to the list to
fish out interesting candidates. (1) Significant MASCOT score: Since on average, individual ions
scores > 44 indicate identity or extensive homology (p < 0.05), we excluded from Mascot lists proteins
identified with a Mascot protein score < 44. After this step, a list of 215 digits remained (140 for S82
and 75 for S104). (2) Single digit for one protein: some proteins are present also in truncated forms
and they are therefore found in different bands. All the multiple digits for the same protein were
removed leaving a list of 139 elements (91 for S82 and 48 for S104). (3) Only human proteins: Mascot
analyses were performed also using mammals as taxonomy. Bovine proteins corresponding to human
ones and identified with the same scores were considered as putative contaminants, and therefore
excluded. After these first steps a list of 85 elements, exclusively human, was left (62 in sample S82
and 23 in sample S104). (4) Proteins present in both S82- and S104-derived exosomes: comparing the
two samples we found only 15 proteins present in both lists (Table 1).
2.3. SEMA7A Is Released on Exosomes
We focused our attention on Semaphorin-L SEMAL, also known as SEMA7A, since it has
been described as a promigratory protein in different physiological conditions [25,27]. Indeed, we
hypothesised that SEMA7A, carried by exosomes, could provide a promoting signal for the invasive
properties of GSCs.
To verify our hypothesis, we first validated the presence of SEMA7A on exosomal preparations
from the producing cell lines used for the proteomic analysis (Figure 2A). Western Blot on S82 and S104
exosomal lysates and on the paired secreting cells lysates confirmed the presence of SEMA7A in both
samples. We also analysed exosomes derived from a human fibroblast cell line Wi38, a mesenchymal
cell line derived from nontumour tissue, as control. We observed that SEMA7A is expressed in the cells,
but not released in vesicles produced by the healthy cell type, suggesting that the release of SEMA7A in
exosomes is a peculiarity of mesenchymal stromal cells resident in the glioblastoma microenvironment.
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Table 1. List of 15 human proteins shared by two GASC-derived exosome preparations analysed by proteomics (Exo_S82, Exo_S104). Seven proteins were already
described in Exocarta database and shown in the right column is a list of sources of exosomes in which they were observed. In bold are highlighted the six proteins not
previously referenced in Exocarta.
Accession Number Protein Exocarta Origin of Exosomes
XP_005257115.2 “collagen alpha-1(I) chain isoform X2 [Homo sapiens]”
CO6A1_HUMAN “Collagen alpha-1(VI) chain OS = Homo sapiens OX = 9606 GN = COL6A1PE = 1 SV = 3” 1291
hepatocellular carcinoma; melanoma, nasopharyngeal carcinoma,
prostate cancer cells; saliva; urina
CO6A2_HUMAN “Collagen alpha-2(VI) chain OS = Homo sapiens OX = 9606 GN = COL6A2PE = 1 SV = 4” 1292 hepatocellular carcinoma; saliva
FBN1_HUMAN “Fibrillin-1 OS = Homo sapiens OX = 9606 GN = FBN1 PE = 1 SV = 3” 2200 endothelial cells
NP_002017.1 “fibronectin isoform 3 pre-proprotein [Homo sapiens]”
LG3BP_HUMAN “Galectin-3-binding protein OS = Homo sapiens OX = 9606 GN =LGALS3BP PE = 1 SV = 1” ovarian cancer
G3P_HUMAN “Glyceraldehyde-3-phosphate dehydrogenase OS = Homo sapiens OX =9606 GN = GAPDH PE = 1 SV = 3” 2597
bladder, breast cancer; colorectal cancer; hepatocellular carcinoma,
intestinal epithelial, melanoma, mesothelioma, neuroblastoma ovarian
cancer, prostate cancer, squamous carcinoma tracheobronchial,
trabecular meshwork cells; aqueous humour; hepatocytes;
keratinocytes; platelets; saliva; urine.
LDHA_HUMAN “L-lactate dehydrogenase A chain OS = Homo sapiens OX = 9606 GN =LDHA PE = 1 SV = 2” 3939
bladder, breast cancer; colorectal cancer; hepatocellular carcinoma,
intestinal epithelial, melanoma, nasopharyngeal carcinoma, ovarian
cancer, prostate cancer, squamous carcinoma cells; hepatocytes;
platelets; thymus; urine
TIMP1_HUMAN “Metalloproteinase inhibitor 1 OS = Homo sapiens OX = 9606 GN = TIMP1PE = 1 SV = 1” 7076
keratinocytes; nasopharyngeal carcinoma cells; squamous carcinoma
cells
PLTP_HUMAN “Phospholipid transfer protein OS = Homo sapiens OX = 9606 GN = PLTPPE = 1 SV = 1” 5360
keratinocytes; platelets; prostate cancer cells; saliva; squamous
carcinoma cells
PAI1_HUMAN “Plasminogen activator inhibitor 1 OS = Homo sapiens OX = 9606 GN =SERPINE1 PE = 1 SV = 1”
AAC34741.1 “semaphorin L partial [Homo sapiens]”
TRFE_HUMAN “Serotransferrin OS = Homo sapiens OX = 9606 GN = TF PE = 1 SV = 3”
QSOX1_HUMAN “Sulfhydryl oxidase 1 OS = Homo sapiens OX = 9606 GN = QSOX1 PE = 1SV = 3”
SJM31191.1 “Sulfotransferase [Homo sapiens]”
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matched producing cells (GASC_S82 and GASC_S104, right panel). As healthy control, SEMA7A 
expression was evaluated both in Wi38 cells and in Wi38-derived exosomes (Exo-Wi38). (B) 
SEMA7A expression was assessed in 4 different GASC cell lines (GASC#1, GASC#2, GASC#3 and 
GASC#4) and in the respective derived exosome preparations (Exo#1, Exo#2, Exo#3 and Exo#4). 
Membranes were hybridised with anti-TSG101 (Tumour Susceptibility Gene 1) and beta-Actin to 
show the reliability of exosomes and cell lysates respectively. (C) Western blot analysis for SEMA7A, 
CD9 and TSG101 in Exo#1 and Exo#2 preparations either untreated (−) or subjected to proteinase K 
treatment (P.K., +). 
2.4. Expression of SEMA7A Receptors on GSC 
Since SEMA7A is exposed on the surfaces of GASC-exosomes, we verified whether it could 
interact with receptors expressed on the GSC membrane. 
SEMA7A has been shown to bind to PlexinC1 [25] and to β1-integrin receptors [31]. 
Plexin C1 is a member of a large family of transmembrane receptors with high affinity for 
semaphorins [32]. In neurons, Sema7A-PlexinC1 signalling regulates synapse development and 
neuroglial plasticity [33,34], while, in cancer, PlexinC1 is involved in cell migration and proliferation 
[35].  
The importance of β1-integrin receptors in SEMA7A signalling has been demonstrated by 
Pasterkamp et al. by blocking the binding between Sema7A and its receptor, resulting in the 
inhibition of Sema7A-dependent neurite outgrowth in olfactory bulb neurons [31].  
Therefore, we first verified, by flow cytometry, the presence of the SEMA7A receptors PlexinC1 
and β1-integrin on the surface of GSC. As shown in Figure 3, 97.5 ± 2.12% of GSC expressed 
β1-integrin at high intensity, while the percentage of cells expressing PlexinC1 was almost 
undetectable (mean = 0.3 ± 0.14% positive cells). 
In light of this observation, we hypothesised that SEMA7A exposed on GASC-exosomes could 
signal, through its interaction with β1-integrin, on GSC. 
Figure 2. SEMA7A (Semaphorin7A) is present on the surface of Glioma Associated Stem Cells
(GASC)-derived exosomes. (A) Western blotting showing the expression of SEMA7A in the same
exosomal preparations used for the proteomic study (Exo_S82 and Exo_S104, left panel) and in the
matched producing cells (GASC_S82 and GASC_S104, right panel). As healthy control, SEMA7A
expression was evaluated both in Wi38 cells and in Wi38-derived exosomes (Exo-Wi38). (B) SEMA7A
expression was assessed in 4 different GASC cell lines (GASC#1, GASC#2, GASC#3 and GASC#4) and
in the respective derived exosome preparations (Exo#1, Exo#2, Exo#3 and Exo#4). Membranes were
hybridised with anti-TSG101 (Tumour Susceptibility Gene 1) and beta-Actin to show the reliability of
exosomes and cell lysates respectively. (C) Western blot analysis for SEMA7A, CD9 and TSG101 in
Exo#1 and Exo#2 preparations either untreated (−) or subjected to proteinase K treatment (P.K., +).
The presence of SEMA7A was further confirmed in the 4 GASC cell lines and relative exosomes,
subsequently used in functional experiments (Figure 2B).
SEMA7A is a glycosylphosphatidylinositol-linked membrane protein that, once released by the
cells, ca be either found in the vesicular membrane or inside the membrane bilayer [30].
To elucidate where SEMA7A is accumulat d in exosomes, we treated intact exosomes with
Proteinase K, a broad substrate-specific endopeptidase. As showed in Figure 2C, Proteinase K
complet ly removed SEMA7A, similarly to the multipass e brane tetras anin CD9, while the inner
TSG101 (Tumour Susceptibility Gene-101) was not affected by digestion, sup orting the id a that
SEMA7A is exposed on the external side of exosomes and therefore could signal directly on the
target cells.
2.4. Expression of SEMA7A Receptors on GSC
Since SEMA7A is exposed on the surfaces of GASC-exosomes, we verified whether it could
interact with receptors expressed on the GSC membrane.
SEMA7A has been shown to bind to PlexinC1 [25] and to β1-integrin receptors [31].
Plexin C1 is a member of a large family of transmembrane receptors with high affinity for
semaphorins [32]. In neurons, Sema7A-PlexinC1 signalling regulates synapse development and
neuroglial plasticity [33,34], while, in cancer, PlexinC1 is involved in cell migration and proliferation [35].
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The importance of β1-integrin receptors in SEMA7A signalling has been demonstrated by
Pasterkamp et al. by blocking the binding between Sema7A and its receptor, resulting in the inhibition
of Sema7A-dependent neurite outgrowth in olfactory bulb neurons [31].
Therefore, we first verified, by flow cytometry, the presence of the SEMA7A receptors PlexinC1
and β1-integrin on the surface of GSC. As shown in Figure 3, 97.5 ± 2.12% of GSC expressed β1-integrin
at high intensity, while the percentage of cells expressing PlexinC1 was almost undetectable (mean =
0.3 ± 0.14% positive cells).Cancers 2019, 11, 758 7 of 20 
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Figure 3. Expression of SEMA7A (Semaphorin7A) receptors on Glioma Stem Cells (GSC). Representative
flow cytometry analysis showing the level of Plexin C1 and Integrin β1 on the surface of two GSC cell
populations. The percentage of positive cells was calculated within the R1-Gate, representing the GSC
population based on forward and side scatter (FSC/SSC) parameters. Histograms overlays show isotype
control staining profile (green histograms) versus specific antibody staining profile (red histograms).
In light of this observation, we hypothesised that SEMA7A exposed on GASC-exosomes could
signal, through its interaction with β1-integrin, on GSC.
2.5. SEMA7A and Exosomes Activates FAK Signalling through β1-Integrin on GSC
The most relevant pathway activated by Integrin receptors is the nonreceptor protein tyrosine
kinase focal adhesion kinase (FAK), which is rapidly phosphorylated after integrin receptor binding,
leading to the activation of cytoskeleton proteins responsible for integrin signal propagation [36].
To verify whether SEMA7A activates FAK pathway, we treated GSC with exogenous recombinant
SEMA7A-Fc, for 2, 5 and 10 min at the concentration of 10 ng/mL and 100 ng/mL, and assessed the
level of tyrosine phosphorylation (Tyr397) of FAK (p-FAK) by Western blot (Figure 4A). As shown in
Figure 4B, SEMA7A-Fc treatment increased the level of FAK phosphorylation and the peak of p-FAK
was observed at 5 min with a concentration of 100 ng/mL (p < 0.0001 vs. untreated cells, Ctrl). Likewise,
the treatment of GSC with exosomes, at a concentration of 10 µg/mL, increased the level of p-FAK after
5 and 10 min (p = 0.0002 vs. Ctrl cells). Conversely, maintaining exosomes for 30 min, diminished
the p-FAK at levels of control (Figure 4C,D). We therefore choose the concentration of 100 ng/mL for
SEMA7A-Fc and 10 µg/mL for GASC-exosome to exploit their effect on GSC motility.
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(Alliance Uvitec, Ltd. Cambridge, UK) to quantify the level of FAK (Focal Adhesion Kinase) 
phosphorylation. Histograms represent results reported as fold change of p-FAK of treated vs. 
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pFAK/FAK after normalisation on beta actin level. Data are presented as mean ± standard deviation 
(n = 4). *** p < 0.001 vs. Ctrl; * p < 0.05 vs. Ctrl. Statistical analysis was performed by repeated 
measurements one-way Anova followed by Bonferroni Multiple Comparison post-test (GraphPad 
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monolayer with a tip and the distance covered after treatment with recombinant SEMA7A-Fc (100 
ng/mL) and GASC-exosomes (10 μg/mL) were measured, after 8 and 24 h. As shown in Figure 5, 
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Figure 4. SEMA7A (Semaphorin7A) and Glioma Associated Stem Cells (GASC)-derived exosomes
activate FAK signalling on glioma stem cells. (A,B) Glioma Stem Cells (GSC) were treated with either
recombinant SEMA7A-Fc for 2, 5 and 10 min at 10 ng/ L or 100 ng/mL and paired GASC-derived
exosomes (10µg/mL) for 5, 10 and 30 min (C,D). Total cells lysates were resolved on 10% Sodium Dodecyl
Sulphate PolyAcrylamide Gel Electrophoresis (S S-PAGE) and blotted to identify the phosphorylated
and non-phosphorylated form of focal adhesion kinase protein (FAK) (A,C). (B,D) Densitometric
analysis was performed using the software available in the Gel-doc instrument (Alliance Uvitec, Ltd.
Cambridge, UK) to quantify the level of FAK (Focal Adhesion Kinase) phosp orylation. Histograms
represent results reported as fold change of p-FAK of treated vs. untreated cells (Ctrl). Values were
calculated as the ratio of IOD (Integrat d Optical D nsity) pFAK/FAK after normalisation on beta actin
level. Data are presented as mean ± standard devi tion (n = 4). *** p < 0.001 vs. Ctrl; * p < 0.05 vs. Ctrl.
Statistical an lysis was performed by repeated m asurements one-way Anova followed by Bonferroni
Multiple Comparison post-test (GraphPad Prism 5).
2.6. SEMA7A and Exosomes Increases GSC Motility
We performed a motility scratch assay to investigate whether SEMA7A-Fc treatment affected the
migratory properties of GSC. A gap was obtained in confluent GSC by scratching the cell monolayer
with a tip and the distance covered after treatment with recombinant SEMA7A-Fc (100 ng/mL) and
GASC-exosomes (10 µg/mL) were measured, after 8 and 24 h. As shown in Figure 5, cells treated with
SEMA7A-Fc were significantly faster in repairing the gap co pared to control (covered distance in 8 h
= 169 ± 21.9 µm vs. 69.62 ± 25.50 µm in SEMA7A-Fc treated and Ctrl cells, respectively). Likewise, a
significant improvement in the motility of GSC was observed after treatments with exosomes (covered
distance in 8 h = 198.8 ± 63. 9 µm). Thus, SEMA7A represents a promigratory signal for GSCs, and
this effect is presumably mediated by FAK pathway activation.
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Figure 5. SEMA-7A (Semaphorin7A) and Glioma Associated Stem Cells (GASC)-derived exosomes
stimulate motility of Glioma Stem Cells (GSC) cell populations. (A) Representative images of scratched
GSC cultures untreated (Ctrl), exposed to SEMA-7A-Fc 100 ng/mL (SEMA7A) or GASC-derived
exosomes (Exo) for 8 and 24 h. (B,C) Distance covered by cells treated as described in (A) and untreated
cells (Ctrl) after 8 (B) and 24 h (C) was calculated measuring the width of the gap between the two
margins of scratched monolayer. Scale bar = 200 µm. Data are presented as means ± standard deviation
of 4 replicates (* p< 0.01 vs. Ctrl). Statistical analysis was performed by repeated measurements one-way
ANOVA followed by Dunn’s Multiple Comparison post-test (GraphPad Prism 5, San Diego, California).
2.7. Impact of SEMA7A-β1-Integrin Receptor Pathway on GSC Motility
To show that β1-integrin is the intermediate receptor between SEMA7A-exosomes and FAK in
GSC, we first tested a functional blocking antibody to β1-integrin on GSC and evaluated changes of
p-FAK, as described above (Figure 4).
Figure 6A,B shows that (1) FAK was quickly phosphorylated after exposure to SEMA7A-Fc and
GASC-exosomes; (2) FAK phosphorylation was abrogated when cells were treated by anti-β1-integrin
antibody; and (3) FAK phosphorylation was not recovered despite the addition of SEMA7A-Fc
or GASC-exosomes.
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Figure 6. Blocking integrin beta1 on GSC (Glioma Stem Cells) affects the activation of Focal Adhesion
Kinase (FAK) signalling and the motility of Glioma Stem Cells (GSC) induced by either Semaphorin7A
(SEMA7A) or Glioma Associated Stem Cells (GASC)-derived exo omes. (A) Representative Western
blotting for FAK and pFAK of GSC treated with anti-Immunoglobulin G (Anti-IgG) antibody, 5 µg/mL
for 65 min, anti-Immunoglobulin G (anti-IgG)antibody, 5 µg/mL for 60 min and SEMA7A 100 ng/mL for
5 min, a ti-IgG antibody 5 µg/mL for 60 i a d GASC-derived exosomes 10 µg/mL for 5 min, SEMA7A
100 ng/mL for 5 min, GASC-derived exosomes 10 µg/mL for 5 min, anti-Integrin beta 1 blocking antibody
5 µg/mL for 65 min, anti-Integrin blocking antibody 5 µg/mL for 60 min and SEMA7A 100 ng/mL for
5 min and anti-Integrin blocking antibody 5 µg/mL for 60 min and GASC-derived exosomes 10 µg/mL
for 5 min. (B) Densitometric analysis was performed using the software available in the Gel-doc
instrument (Alliance Uvitec, Ltd. Cambridge, UK) to quantify the level of FAK phosphorylation. The
histogram represents results reported as the Fold Change of p-FAK of different treatments vs. cells
treated with the anti-IgG antibody. Values were calculated as the ratio of IOD (Integrated Optical
Density) pFAK/FAK after normalisation on beta actin level. (C) A motility assay was performed in cells
treated as described in B. Histogram represents the distance covered after 8 h, calculated measuring
the width of the gap between the two margins of scratched monolayer. Data are presented as means
± standard deviation of 4 replicates. * p < 0.05 vs. Anti-IgG, ** p < 0.05 vs. Anti-IgG+SEMA-7A,
*** p < 0.05 vs. Anti-IgG+ Exo, § p < 0.05 vs. SEMA-7A, ◦ p < 0.05 vs. Exo. Statistical analysis was
performed by repeated measurements one-way ANOVA followed by Bonferroni Multiple Comparison
post-test (GraphPad Prism 5, San Diego, California).
Therefore, the inactivation of β1-integrin receptor completely neutralised the activation of the FAK
pathway stimulated by SEMA7A or GASC-exosomes. This effect was specific to β1 blocking antibody,
since treating GSC with an unrelated antibody (anti-mouse IgG), had no effect on SEMA7A-mediated
FAK phosphorylation.
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To test whether the molecular interference on SEMA7A-β1-integrin-FAK might impact on GSC
motility, we performed a Scratch assay to evaluate the GSC’s migratory performances, following
exposure to recombinant SEMA7A-Fc alone, in combination with anti-β1-integrin blocking antibody
or with anti-mouse IgG as control. Since our hypothesis is that SEMA7A transported by exosomes
in the glioma microenvironment could be responsible, at least in part, of the promigratory effect
on GSC, we performed a Scratch assay on GSC exposed to exosomes alone or in combination with
β1-Integrin-blocking antibody. Histograms in Figure 6C clearly show that the distance covered by
SEMA7A-Fc and exosomes-treated cells measured after 8 h (133.3 ± 42.26µm and 174 ± 51.23 µm,
respectively), was significantly longer when compared with cells treated with anti-mouse IgG antibody
(79.30 ± 20.66 µm). When the binding of SEMA7A-exosomes with β1-integrin receptor was inhibited,
cells were significantly slower (37.32± 22.95 µm) and their migration was not restored after SEMA7A-Fc
or exosomes introduction (62.07 ± 31.46 µm and 55.20 ± 30.43 µm, respectively).
Therefore, our results strongly suggest that SEMA7A exposed on GASC-released exosomes, upon
binding to β1-integrin on the surface of GSCs, accelerates their migration, which is correlated with
tumour aggressiveness.
3. Discussion
It is well known that glioblastoma cells subvert their microenvironment from a tumour-suppressive
to a tumour-supporting condition, which promotes proliferation, angiogenesis and invasion [7]. This
phenomenon requires a continuous cross-talk between tumour cells and nontumour components, such
as stromal cells, extracellular matrix and immune cells [37].
In our previously established in vitro model of GBM microenvironment, we found that exosomes,
released by GASC, have a tumour-supporting role towards GSC [19].
Therefore, we performed a descriptive proteomic analysis of exosomes released by GASC, to
understand which components could be involved in the GASC tumour-supporting function.
Results from mass spectrometry revealed 15 proteins present in both exosomes preparations
analysed. Overall, all the proteins found in this study could contribute to the tumour-supporting
function of GASC’ exosomes. Fibronectin1 FBN1, TIMP metalloprotease inhibitor 1)(TIMP1) and
Phospholipid transfer protein (PLTP) were described as promoter of metastasis, resistance to apoptosis
and migratory properties in ovarian cancer, melanoma and glioma, respectively [38–40]; Collagen
Alpha-1 (VI) chain (COL6A1) and Collagen Alpha-2 (VI) chain (COL6A2) are involved in the guidance of
neural crest cells, during CNS development [41] and in the motoneuron axon growth [42]; plasminogen
activator inhibitor-1 (PAI-1), is a well-known marker overexpressed in several forms of cancer [43];
Galectin-3-binding protein promotes integrin-mediated cell adhesion [44] and has been found elevated
in the serum of patients with cancer [45], although not present in Exocarta, it has been described in the
exosomes of ovarian carcinoma cells [46] and it has been suggested to be an important component of
tumour microenvironment [47]; Serotransferrin (transferrin) is an abundant blood plasma glycoprotein
whose main function is to bind and transport iron throughout the body. Interestingly, Carlsson et al.,
2013 [48] showed that ~5% of human serotransferrin glycoforms bind galectin-3 and are targeted to a
different endocytic pathway and that the galectin-3-bound glycoform is increased in cancer. Although
eight out of 15 proteins have been previously described in exosomes of some sources, five of them
are completely new. Among these, we focused our attention on SEMA7A, because of its role in
physiological and pathological conditions. One of the first study showed that SEMA7A has a function
on the immune system, being a potent activator of monocytes, stimulating their chemotaxis and
production of inflammatory cytokines [49]. Pasterkamp et al. were the first to describe SEMA7A as a
guidance signal responsible to stimulate axon outgrowth, during the formation of lateral olfactory
tracts [31]. The authors showed that SEMA7A binds to integrin beta1 receptors and activates the
mitogen activated protein kinase pathway (MAPK). Moreover, the use of a beta-1 integrin inhibitory
antibody blocked the neurite outgrowth. Moreover, SEMA7A is expressed in the secretome of U87
glioblastoma cells at higher level than in less aggressive and invasive cell lines (T98, U118) [50].
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In summary SEMA7A can be regarded as a promigratory stimulus and since motility of glioma
cells is one of the properties responsible for the infiltrative nature of GBM, we hypothesised that
SEMA7A, released by GASC through exosomes, can act as one of the messages stimulating GSC
motility/migration.
We confirmed both the presence of SEMA7A on four exosome preparations and, most importantly,
its exposure on the external surface of exosomes. On the other hand, cytofluorimetric analysis revealed
the presence of integrin beta 1, but not Plexin C1—two major SEMA7A receptors—on glioma stem
cells (GSCs). This suggested that SEMA7A could directly signal to GSC through integrin beta1.
Integrins represent the major cellular receptors for extracellular matrix involved in the regulation
of cell migration through their coupling with cytoskeletal and signalling molecules, clustering in focal
adhesion in adherent cells and Focal adhesion kinase (FAK) has been established as a key component
of signal transduction triggered by integrins [51]. Autophosphorylation and activation of FAK lead to
modulation of cytoskeletal proteins, cytoskeletal reorganisation and force generation [52,53].
Regulation of cell migration by integrin signalling through FAK leading to cancer pathogenesis
and aggressiveness has been assessed in many cell types [54]. β1 integrins have been implicated in
brain invasion of glioma cells in animal models using antisense RNA to reduce integrin expression [55].
In our in vitro model, relying on GASC and GSC obtained from the same tumour, the treatment
of GSC, both with recombinant SEMA7A-Fc and exosomes produced by GASC, stimulated a rapid
FAK phosphorylation and significantly increased the motility of GSC. Using an antibody blocking
β1-integrin receptors, we observed a reduction of FAK activation at the level of the control and a
decreased speed of GSC, in covering the gap generated in the motility assay. Concomitant addition of
SEMA7AFc or GASC-exosomes to anti-integrin beta1 antibody was not able to rescue FAK engagement
or motility of GSC.
The involvement of SEMA7A-integrin β1 in cell migration and tumour invasiveness is not
completely new: Black et al. identified a high expression of SEMA7A in ductal in situ breast cancer
characterised by poor prognosis and distant metastases, and showed the involvement of SEMA7A in
promoting tumour cell invasion and lymphangiogenesis, via activation of β1-integrin [29].
Moreover, other members of the semaphorin family were identified in exosomes of the glioblastoma
microenvironment. SEMA3A released in GSC’ exosomes disrupt the endothelial barrier, thus promoting
the vascular permeability and invasion in the surrounding brain parenchyma [56].
The novelty of our work is to indicate, for the first time, the interaction SEMA7A-β1-integrin as a
new mediator in the cross-talk occurring in the glioma microenvironment between exosomes produced
by glioma stromal cells and GSC, becoming an interesting new possible therapeutic target
In fact, integrin ligand binding and regulatory sites are externally exposed and made them good
accessible drug candidates [57]. Indeed, many inhibitors have been developed. Of the number of
clinical trials started, some reached late stage and some inhibitors have even launched for treatment.
Of the Intβ1 inhibitors evaluated in the clinical trials, a pan β1 monoclonal antibody P5 (claimed to
predominantly act on α5β1) is reported to enhance cisplatin efficacy in lung adenocarcinoma cells and
is in use in phase 3 trial for non-small cell lung cancer [58].
In the light of our result it would be interesting to further investigate the possibility to reduce
tumour infiltration by the use of β1 inhibitors like the P5 antibody.
Altogether our results give new insights on how stromal cells in the glioblastoma microenvironment
could contribute to the increased aggressiveness of the tumour.
4. Materials and Methods
4.1. Isolation and Culture of GASC and GSC
Cells were isolated from patients affected by a de novo supratentorial glioblastoma
(GBM). All patients, not previously treated, underwent surgical resection of the tumour at the
Neurosurgery Department of the Udine Hospital. The independent ethic committee of the Azienda
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Ospedaliero-Universitaria of Udine has approved the research (Consent 102/2011/Sper, 02 August,
2011 and Consent 196/2014/Em, 03 December, 2014). Written informed consents were obtained from
all patients and clinical investigations have been conducted according to the Declaration of Helsinki.
GASC were isolated from 6 tumour samples, as previously described [19]. In 4 cases, GSCs from the
same tumour samples were cultured [59] in order to have 4 GASC-GSC pairs. See Appendix A.
4.2. Isolation of Exosomes
Cells were cultured in expansion medium for three passages and then seeded at 6000 cells/cm2
in 100 mm Petri dishes. After 24 h, expansion medium was replaced with a serum–linoleic acid
bovine serum albumin-depleted medium. Cells were maintained until 70–80% confluence (48 h).
Wi38 cells were cultured in Dulbecco’s Modified Eagle Medium D-MEM+10% exosome-depleted
foetal bovine serum. Exosomes were isolated from the collected supernatants using ExoQuick-TC
Exosome precipitation solution (System Biosciences, Palo Alto, California), according to manufacturer’s
protocol. The exosomal pellets were resuspended in phosphate-buffered saline (PBS) or radio
immunoprecipitation assay (RIPA) buffer; see Appendix A.
4.3. Nanoparticle Tracking Analysis
Concentration and particle size of purified exosomes were measured by Nanosight (LM10, Malvern
system Ltd., U.K.), equipped with a 405 nm laser. Briefly, each sample, once properly diluted, was
recorded for 60 s with a detection threshold set at maximum. Temperature was monitored throughout
the measurements. Vesicle size distribution and an estimated concentration of NTA (Nanoparticle
Tracking Analysis) profiles were obtained from the given raw data files.
4.4. Proteomic Analyses
For proteomic analysis, 30 µg of total exosomal proteins obtained from two different GASC
cultures (S82 and S104) were used. Protein lysates were separated on SDS-PAGE (Gel Tris-Glycine
10%) and the gel was cut to divide samples into six macrobands and treated essentially as previously
described [60]. Fragments obtained by in-gel trypsin digestion were analysed by LC–MS/MS with ionic
trap, on an Agilent 1200 series nanoHPLC interfaced to an HCTultra IT (Bruker Daltonics, Billerica,
Massachussetts). Peptide masses and MS/MS spectra were exported as ‘mgf’ files and database search
was performed with the MASCOT MS/MS (Mascot-Peptide mass finger-print) Ion Search option). See
Appendix A.
4.5. Western Blot
Whole-cell and exosomes extract proteins were obtained by lysis in RIPA buffer. Thirty micrograms
of proteins was resolved on SDS-PAGE, transferred and immobilised on a 0.45 µm nitrocellulose
membrane (Amersham, London, UK).
Membranes were incubated overnight at 4 ◦C, with goat polyclonal to CD63 (LSBio, Seattle,
Washington) mouse monoclonal to CD9 (Clone Ts9) (Thermo Fisher, Walthman, Massachussetts) mouse
monoclonal to TSG101 (Clone 4A10) (Abcam, Cambridge, UK), rabbit polyclonal to Calnexin (Abcam
rabbit polyclonal to SEMA7A (Novus Biologicals, Colorado, US) and rabbit polyclonal to beta-Actin
(Sigma-Aldrich, Italy). Primary antibodies were detected using horseradish peroxidase-linked
secondary antibodies (DAKO, Cambridge, UK) and visualised using the enhanced chemiluminescent
detection system (SuperSignal West Dura Extended Duration Substrate, Thermo Scientific, Walthman,
Massachussetts); see Appendix A.
4.6. Proteinase K Treatment of GASC-Exosomes
30 µg of GASC-derived exosomes resuspended in PBS were incubated with 100 µg/mL Proteinase
K (Sigma-Aldrich, Italy) or the same volume of water as control, for 1 h, at 37 ◦C, with regular shaking.
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Proteinase K was inhibited with phenylmethylsulfonyl fluoride PMSF 5 mM treatment for 10 min at
72 ◦C. Exosomes were then lysed and analysed by western blot.
4.7. Flow Cytometry
Proliferating GSC were detached with TRYPLE Express (Gibco Walthman, Massachussetts) and
incubated with conjugated primary antibody anti-integrin beta 1 (CD29-APC, BD-Biosciences) or
unconjugated goat anti-human PlexinC1 (Invitrogen, Carlsband, California). Plexin C1 was revealed
using Alexa-Fluor 647 donkey anti-goat secondary antibody (Jackson ImmunoResearch, Cambridge,
UK). Plexin C1 expression was previously evaluated on human CD14+ monocytes (positive control,
Figure S1), as detailed in Appendix A. Proper conjugated isotype matched antibodies were used as
negative control.
At least 2 × 104 events were collected by FACS CANTO II (Becton Dickinson (BD)-Biosciences,
US) and analysed using Summit Software (Dako Cytomation, Denmark).
4.8. Evaluation of FAK Phosphorylation (Tyr-397) after SEMA7A and GASC-Exosome Stimulation or Integrin
Beta1 Blocking on GSC
GSC were seeded at 1 × 104/cm2 in complete Neurobasal-A medium. After 24 h, cells were treated
with Human Recombinant SEMA7A Fc Chimera (R&D System, Minneapolis, Minnesota) for 2, 5 or
10 min at 10 or 100 ng/mL or untreated.
For treatments with GASC-exosomes, GSCs were exposed to 10 µg/mL of exosomes for 5, 10 and
30 min. For treatments with anti-integrin beta1 blocking antibody, GSC were treated as detailed in
Appendix A.
Cells were washed in cold PBS, immediately harvested in RIPA buffer, at 4 ◦C, and proteins were
extracted as previously described. Twenty micrograms of proteins was resolved on 10% SDS/PAGE,
and then transferred and immobilised on a 0.45 µm nitrocellulose membrane, (Amersham).
The membranes were incubated with rabbit-anti human to FAK antibody, rabbit-anti human to
phospho-FAK (Tyr-397) antibody (Cell Signalling Technology, Danvers, Massachusetts) and with rabbit
polyclonal to beta-Actin. Levels of FAK and p-FAK were evaluated by densiometric analysis, using
ImageJ. IOD (Integrated Optical Density) was analysed for each condition and Fold Change of p-FAK
was calculated vs. untreated (Ctrl) cells, after normalisation on β -actin expression.
4.9. Scratch Assay
GSC were seeded on 48-well plates at 3 × 104 cell/cm2. At confluence, the cell monolayer was
straight-scraped with a p10 pipette tip. Cellular debris was removed and culture medium was replaced
with fresh one containing the treatments described in Appendix A. Each experimental condition was
performed four-fold. Images were acquired at 8 h and 24 h after treatments, by a Leica DMI 6000B
microscope connected to a Leica DFC350FX camera (10× objective, numerical aperture 0.25, Wetzlar,
Germany). Images were then compared and quantified by Image J.
5. Conclusions
In this study, we described for the first time SEMA7A-integrin β1 interaction as a new mediator
of the cross-talk occurring between microenvironment and glioma stem cells, through the release of
exosomes. This interaction could be regarded as a new therapeutic target in the GBM field.
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Appendix A.
Appendix A.1. Methods
Appendix A.1.1. Isolation and Culture of Glioma-Associated Stem Cells and Glioma Stem Cells
Glioblastoma (GBM, grade IV glioma) fragments were first disaggregated mechanically with
scalpels, and then enzymatically dissociated in a 0.025% Collagenase Type II solution (Worthington,
UK, ) in Joklik Modified Eagle’s Medium (Sigma-Aldrich, Italy) for 5 min at 37 ◦C. Collagenase activity
was then neutralised by the addition of 10% Fetal Bovine Serum in Joklik modified Eagle’s Medium
(Sigma-Aldrich, Italy). Cell suspension was centrifuged at 500 g for 10 min and filtered through a sieve
(BD Falcon, US) in order to select a population less than 40 µm in diameter. Two-million freshly isolated
human cells were plated onto 100 mm diameter, human fibronectin (Sigma-Aldrich, Italy)-coated dishes
(BD Falcon), in an expansion medium composed as follows; 60% low glucose Dulbecco’s Modified
Eagle’s Medium (DMEM, Gibco, Walthman, Massachussetts), 40% MCDB-201, 1mg/mL linoleic
acid-BSA, 10−9 M dexamethasone, 10−4 M ascorbic acid-2 phosphate, 1X insulin-transferrin-sodium
selenite (all from Sigma-Aldrich, Italy), 2% fetal bovine serum (StemCell Technologies, Mexico),
10 ng/mL human PDGF-BB and 10 ng/mL human EGF (both from Peprotech EC). GSC were isolated
from the same patients’ biopsy using the aforementioned protocol, but seeded at a density of
2 × 104 cells/cm2 onto laminin (Laminin from Engelbreth-Holm-Swarm murine sarcoma basement
membrane, Sigma-Aldrich, Italy)-coated dishes in a growing serum-free medium composed as follows;
Neurobasal-A medium (Gibco Walthman, Massachussetts), 2 mM L-glutamine (Sigma-Aldrich, Italy),
1X N2 supplement (Gibco Walthman, Massachussetts), 25 µg/mL Insulin, Penicillin-streptomycin,
100 µg/mL human apo-trasferrin (Sigma-Aldrich, Italy), 1× B-27 supplement (Gibco, Walthman,
Massachussetts), 20 ng/mL h-FGF-basic (Peprotech, UK) and 20 ng/mL h-EGF (Peprotech, UK). Both
cell populations were cultured in an incubator at 37 ◦C, 5% O2/5% CO2. Half medium was replaced
with fresh one every 4 days. Once cells reached 70 ± 80% of confluence, they were detached with
TrypLE Express (Invitrogen, Carlsband, California) and re-plated at a density of 3 × 103/cm2 and
1 × 104/cm2 (GASC and GSC, respectively).
Appendix A.1.2. Isolation of Exosomes
Supernatants were collected after 48 h conditioning, centrifuged at 3000 g for 30 min at 4 ◦C
to remove cells and debris and filtered through a 0.2 µm filter to remove particles larger than
200 nm. Supernatants were then concentrated using centrifugal filter units (Amico-Ultra15, Merck
Millipore, Burlington, Massachussetts) in regenerated cellulose membranes, with pore size of 100 kDa,
by centrifuge at 4700 g for 20 min at 4 ◦C. The ultrafiltered supernatants were then incubated
with ExoQuick-TC Exosome precipitation solution (System Biosciences, Palo Alto, California) in
a 5:1 dilution overnight at 4 ◦C and centrifuged at 1500 g, 15 min at 4 ◦C. Exosomal pellets were
dissolved in PBS or RIPA buffer (NaCl 150 mM, 25 mM Tris-HCl, pH 7.6, 1% IGEPAL, (Octylphenoxy
poly(ethyleneoxy)ethanol), 0.1% SDS, 1% SodiumDeoxycholate, 1 mM dithiothreitol, 1 mM Na2 VO4,
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1 mM Sodium Fluoride, 0.5 mM Phenylmethanesulfonyl fluoride, Protease Inhibitor Cocktail), based
on future applications.
Appendix A.2. Proteomic Analyses
Appendix A.2.1. In-gel Digestion and LC–MS/MS Analyses
Proteins extracted from exosomes were separated on 10% SDS polyacrylamide gel, stained with
R250 Coomassie Brilliant Blue (CBB) and destained with 10% acetic acid. Electrophoretic lanes were cut
into six equivalent parts—>130 kDa, 97–130 kDa, 66–97 kDa, 47–66 kDa, 40–47 kDa and 26–36 kDa—and
processed essentially as previously described (40). LC–MS/MS analyses were performed on an Agilent
1200 series nanoHPLC (High Performance Liquid Chromatography) interfaced to an HCTultra IT
(Bruker Daltonics, Billerica, Massachussetts). 20 out of 30 µL resuspended peptides were loaded at a
flow rate of 15 µL/min on a trap column (300SB–C18 USP L1 0.3 × 5 mm, 5 µm, Agilent) for 5 min
with 98% H2O, 2% ACN and 0.1% TFA. The trap column was then connected to the analytical column
(Zorbax Nano RR 300SB–C18 0.075 × 150 mm, 3.5 µm) and the peptides eluted with a linear H2O/ACN
(Acetonitrile) gradient (Solvent A: H2O 0.1% HCOOH, Solvent B: ACN 0.1% HCOOH; 60 min gradient
from 2 to 60% Solvent B; flow: 200 nL/min). Eluted peptides were analysed online with an HCTultra
IT (Bruker Daltonics, Billerica, Massachussetts) using a nanoelectrospray interface. IT control was
performed by the Esquire Control software (version 6.1, Bruker Daltonics, Billerica, Massachussetts).
LC–MS/MS analyses were elaborated with the Data Analysis software (version 3.4, Bruker Daltonics,
Billerica, Massachussetts ). Peptide masses and MS/MS spectra were exported as ‘.mgf’ files and
database search was performed with the MASCOT MS/MS Ion Search option: database: NCBIprot
and SwissProt; taxonomy: Homo sapiens (human); enzyme: trypsin; allowing up to three instances of
missed cleavage; Fixed modification: none; variable modification: none; peptide tol.: 1.2 Da; MS/MS
tol.: 0.6 Da; peptide charge: 2 and 3; mass: monoisotopic; Instrument: ESI-TRAP. Mascot analyses were
performed also using Mammalia (mammals) as taxonomy. Bovine proteins corresponding to human
ones and identified with the same scores were considered as putative contaminants and evidenced
in red within the reported tables. Since on average, individual ions scores >44 indicate identity or
extensive homology (p < 0.05) we excluded from Mascot lists proteins identified with only one peptide
and with a Mascot protein score <44. Raw MS data (.mgf) are available upon request.
Appendix A.2.2. Isolation and Staining of CD14 Positive Monocytes from Human Blood Samples
CD14 positive monocytes were used as positive control to evaluate the expression of PlexinC1.
To isolate CD14+ cells, whole blood samples from healthy donors were collected in EDTA (ethylene
diamine tetra-acetic acid) -tubes by the Department of Transfusion Medicine (University Hospital
of Udine) after a written informed consent was signed. PBMCs were separated by centrifugation at
700 g for 20 min on a Ficoll Hypaque density gradient (Millipore, Burlington, Massachussetts) and
resuspended at 1× 106 cells/mL in 0,5% bovine serum albumin (BSA), 2 mM EDTA in phosphate buffered
saline (PBS), pH 7.2. CD14+ cells were purified from PBMCS (Peripheral Blood Mononuclear Cells)
after immuno-magnetic labelling with CD14 Microbeads (MACS-Miltenyi Biotec, Bergisch Gladbach,
Germany) by positive selection in a magnetic field, following manufacturer’s suggestion (Miltenyi
Biotec, Bergisch Gladbach, Germany). Cells were double-stained with conjugated primary antibody
to CD14-APC (BD-Biosciences, US) and unconjugated goat anti-human to PlexinC1 (Invitrogen,
Carlsband, California ) at 0.2 µg/104 cells. Plexin C1 was revealed using Alexa-Fluor 647 donkey
anti-goat secondary antibody (Jackson ImmunoResearch, Cambridge, UK), diluted 1:800. Properly
conjugated isotype matched antibodies were used as negative control.
Appendix A.2.3. Western Blot
Whole-cell extract proteins were obtained by cells’ lysis in RIPA Buffer for 40 min on ice and
centrifugation at 10.000 g for 15 min at 4 ◦C, and then the protein-enriched supernatants were collected.
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The extraction of proteins from exosomes was performed using the above described RIPA buffer, for 30
min at 4 ◦C. Proteins concentration was measured by BCA protein assay (Euroclone, Italy).
30 µg of proteins were resolved on SDS-PAGE, transferred and immobilised on a 0.45 µm
nitrocellulose membrane (Amersham, London, UK).
Membranes were blocked by incubation for 1 h at room temperature, with 5% non-fat milk or 5%
Bovine Serum Albumin in TBS (Tris-HCl 50 mM, pH 7.4, NaCl 150 mM) containing 0.2% Tween 20
and hybridised, overnight at 4 ◦C, with goat polyclonal to CD63 (LSBio, Seattle, Washington) diluted
1:500, mouse monoclonal to CD9 (Clone Ts9) (Thermo Fisher, Walthman, Massachussetts) diluted
1:1000, mouse monoclonal to TSG101 (Clone 4A10) (Abcam, Cambridge, UK), diluted 1:1000, rabbit
polyclonal to Calnexin (Abcam, Cambridge, UK), diluted 1:1000, rabbit polyclonal to SEMA7A (Novus
Biologicals, Colorado, US), diluted 1:1000 and rabbit polyclonal to beta-Actin (Sigma-Aldrich, Italy),
diluted 1:2000. Primary antibodies were detected using horseradish peroxidase-linked anti-mouse,
anti-rabbit or anti-goat secondary antibodies (DAKO, Cambridge, UK) and visualised using the
enhanced chemiluminescent detection system (SuperSignal West Dura Extended Duration Substrate,
Thermo Scientific, Walthman, Massachussetts).
Appendix A.3. Evaluation of FAK Phosphorylation (Tyr-397) after SEMA7A and GASC-Exosomes Stimulation
or Integrin Beta1 Blocking on GSCs
For treatments with anti-integrin beta1 blocking antibody, GSCs were seeded at 1 × 104/cm2 in
complete Neurobasal-A medium. After 24 h, cells were treated by
1. 100 ng/mL of Sema7A-Fc (R&D System), for 5 min
2. 10 µg/mL of GASC-exosomes, for 5 min
3. 5 µg/mL of Anti-IgG antibody (Millipore), for 65 min
4. 5 µg/mL of Anti-IgG antibody for 60 min, +100 ng/mL of Sema7A-Fc, for 5 min
5. 5 µg/mL of Anti-IgG antibody for 60 min, +10 µg/mL of GASC-exosomes, for 5 min
6. 5 µg/mL of Mouse monoclonal to integrin beta1 [P5D2] (Abcam, ab24693), for 65 min
7. 5 µg/mL of Mouse monoclonal to integrin beta1 for 60 min, +100 ng/mL of Sema7A-Fc, for 5 min;
8. 5 µg/mL of Mouse monoclonal to integrin beta1, for 60 min, +10 µg/mL of GASC-exosomes, for
5 min.
All treatments were performed in a 5% O2/5% CO2 incubator at 37 ◦C, and repeated using four
GSC cell populations and four paired GASC-exosomes preparations.
Cells were washed in cold PBS, immediately harvested in RIPA buffer at 4 ◦C, and proteins were
extracted as previously described. Twenty micrograms of proteins was resolved on 10% SDS/PAGE,
and then transferred and immobilised on a 0.45 µm nitrocellulose membrane, (Amersham).
The membranes were processed as described in the “Western Blot” section, incubated with
rabbit-anti human to FAK antibody and with rabbit-anti human to phospho-FAK (Tyr-397) antibody
(Cell Signalling Technology, Danver, Massachussetts) diluted 1:1000 in 5% Bovine Serum Albumin in
TBS. Levels of FAK and p-FAK expression were evaluated by densitometric analysis, using ImageJ.
IOD (Integrated Optical Density) was analysed for each condition and pFAK/FAK ratio was calculated,
after normalisation on β-actin expression.
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